H5N1 News and Research

Latest H5N1 News and Research

Sinovac Biotech announces financial update, new joint ventures and developments

Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, today announced the following recent developments.

21 Jan 2010

SVA plans to sell 8,650,000 common shares in an underwritten public offering

Sinovac Biotech Ltd. ( SVA), a leading China-based vaccine manufacturer, today announced that it plans to sell, subject to market and other conditions, 8,650,000 common shares of the company in an underwritten public offering.

21 Jan 2010

Sirnaomics certifies polypeptide nanoparticle technology

Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has licensed a polypeptide nanoparticle technology invented by Professor A. James Mixson of University of Maryland Medical School.

18 Jan 2010

AVIR Green Hills Biotechnology commences deltaFLU Phase II study

AVIR Green Hills Biotechnology, the innovative biotech company based in Vienna, has started the New Year by embarking on the first clinical phase II study for the seasonal vaccine deltaFLU. The study will be carried out at the Medical University of Vienna. With this step, AVIR Green Hills has set yet another important milestone in the development of effective and modern influenza vaccines.

18 Jan 2010

New genetic evidence can improve avian influenza surveillance programs

Genetic analyses of avian influenza in wild birds can help pinpoint likely carrier species and geographic hot spots where Eurasian viruses would be most likely to enter North America, according to new U.S. Geological Survey research.

13 Jan 2010

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

NanoViricides, Inc. (the "Company"), reports that the Company has been invited to present on January 12th at the Biotech Showcase™, a conference designed to showcase promising companies and technologies for partnering and investment purposes.

12 Jan 2010

CEL-SCI completes validation of its GMP manufacturing facility

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today it has completed the validation of all critical utilities and manufacturing equipment at its GMP manufacturing facility in Maryland.

12 Jan 2010

Vienna scientists develop new technique for producing H1N1 vaccines

Scientists in Vienna have developed a new technique for producing vaccines for H1N1, 'swine flu', based on insect cells. The research, published today in the Biotechnology Journal, reveals how influenza vaccines can be produced faster than through the traditional method of egg-based production, revealing a new strategy for the fight against influenza pandemics.

5 Jan 2010

SVA submits the first clinical trial application for HFMD vaccine in China

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has filed the application with China's State Food and Drug Administration (SFDA) to commence a human clinical trial for its vaccine against human enterovirus 71 (EV 71), which causes hand, foot, and mouth disease (HFMD). This is the first clinical trial application for HFMD vaccine submitted in China.

28 Dec 2009

Former CDC head to lead Merck's vaccine division

The pharmaceutical company Merck on Monday named former CDC head Julie Gerberding as president of the company's vaccine division, Reuters reports. "Gerberding, who led the CDC from 2002 to 2009 and stepped down when President Barack Obama took office, will head up the company's $5 billion global vaccine business that includes shots to prevent chickenpox, cervical cancer and pneumonia," the news service reports.

22 Dec 2009

Sinovac Biotech selected as Top 10 most competitive companies for 2009

Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac was selected by China Business Media as one of China's Top 10 most competitive companies listed overseas for 2009.

22 Dec 2009

Positive interim results from Medicago's H5N1 vaccine Phase I human clinical trial

Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase I human clinical trial with its H5N1 Avian Influenza vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

21 Dec 2009

Flu vaccine shortages in developing countries could destabilize global security, says former WHO deputy head

"Flu vaccine shortages in developing nations may destabilize global security should the H1N1 [swine flu] virus become more deadly … David Heymann, a former deputy head of the World Health Organization" said Monday, Bloomberg reports.

10 Dec 2009

Computer search algorithms identify FDA-approved drugs that could be the basis for new medicines

A massive, data-crunching computer search program that matches fragments of potential drug molecules to the known shapes of viral surface proteins has identified several FDA-approved drugs that could be the basis for new medicines -- if emerging viruses such as the H5N1(avian flu) or H1N1/09 (swine flu) develop resistance to current antiviral therapies -- according to a presentation at the American Society for Cell Biology (ASCB) 49th Annual Meeting, Dec. 5-9, 2009 in San Diego.

7 Dec 2009

Eastern Technology Council names Puricore as winner of the Emerging Life Sciences Company of the Year

PuriCore, the life sciences company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, was named as winner of the Emerging Life Sciences Company of the Year award, at the Eastern Technology Council’s 17th annual Enterprise Awards gala.

4 Dec 2009

Expert advice for organ transplant surgeons on clinical issues posed by swine flu pandemic

Surgeons and other healthcare professionals specialising in solid organ transplants have been issued with expert advice to guide them through the complex clinical issues posed by the global H1N1 (swine flu) pandemic.

4 Dec 2009

Positive results from NanoBio's recombinant H5N1 flu antigen-nanoemulsion vaccine combination study

NanoBio Corporation today announced positive results from studies in mice in which immune responses were evaluated following administration of 5µg doses of recombinant H5N1 pandemic flu antigen combined with the company’s novel nanoemulsion vaccine. These studies are unique because the adjuvant was administered for the first time by subcutaneous (SC) and intramuscular (IM) injections.

3 Dec 2009

Sinovac Biotech receives fourth purchase order for its H1N1 vaccine from Chinese government

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has received its fourth purchase order for its H1N1 vaccine, PANFLU.1(TM), from China's Ministry of Industry and Information Technology for the national purchase plan.

2 Dec 2009

CRO to run CEL-SCI's upcoming Phase III clinical trial

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today that it has retained the services of an international Contract Research Organization (CRO) to run CEL-SCI's upcoming Phase III clinical trial in advanced primary head and neck cancer with the Company's lead product candidate, Multikine®.

1 Dec 2009

Akonni Biosystems receives $3.2M Phase II SBIR grant from NIH

Akonni Biosystems, a molecular diagnostics (MDx) company focused on providing rapid and highly scalable solutions for infectious disease testing, today announced receipt of a $3.2M Phase II SBIR grant from the National Institutes of Health (NIH).

1 Dec 2009

H5N1 News and Research

Latest H5N1 News and Research

Sinovac Biotech announces financial update, new joint ventures and developments

SVA plans to sell 8,650,000 common shares in an underwritten public offering

Sirnaomics certifies polypeptide nanoparticle technology

AVIR Green Hills Biotechnology commences deltaFLU Phase II study

New genetic evidence can improve avian influenza surveillance programs

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

CEL-SCI completes validation of its GMP manufacturing facility

Vienna scientists develop new technique for producing H1N1 vaccines

SVA submits the first clinical trial application for HFMD vaccine in China

Former CDC head to lead Merck's vaccine division

Sinovac Biotech selected as Top 10 most competitive companies for 2009

Positive interim results from Medicago's H5N1 vaccine Phase I human clinical trial

Flu vaccine shortages in developing countries could destabilize global security, says former WHO deputy head

Computer search algorithms identify FDA-approved drugs that could be the basis for new medicines

Eastern Technology Council names Puricore as winner of the Emerging Life Sciences Company of the Year

Expert advice for organ transplant surgeons on clinical issues posed by swine flu pandemic

Positive results from NanoBio's recombinant H5N1 flu antigen-nanoemulsion vaccine combination study

Sinovac Biotech receives fourth purchase order for its H1N1 vaccine from Chinese government

CRO to run CEL-SCI's upcoming Phase III clinical trial

Akonni Biosystems receives $3.2M Phase II SBIR grant from NIH

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

H5N1 News and Research

Latest H5N1 News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in